|
|
|
|
|
|
|
Past Events
12.8.11: EPEMED Conference
Luxembourg
Kristin Pothier, Partner, delivered a presentation at the European Personalized Medicine
Association (EPEMED) Conference. The presentation entitled, "Economics of Life Science Innovation and Personalized Medicine," highlighted the business
strategy, financial investment and costs associated with the global expansion of Life Science and Personalized Medicine. This conference brings together
leaders across therapeutics and diagnostics to discuss the challenges and solutions to successful global commercialization of personalized medicine.
 learn more about our expertise in personalized medicine.
11.7.11-11.8.11: Partnering for Cures 2011
New York, NY
Marie Schiller, Partner, served as an Expert Consultant at Partnering for Cures 2011. The meeting was an opportunity to find nontraditional allies who can help companies advance their medical research goals, and a platform for solutions needed to accelerate progress.
Convened by FasterCures, a Center of the Milken Institute, this effort brought together more than 800 leaders from all sectors
of the medical research enterprise, across therapeutic areas, and across geographic boundaries.
Marie provided expert consultation in strategic planning, specifically addressing strategic and business model issues
including establishing planning guidelines and timelines, conducting strategic analysis and organizational assessments, setting
or changing strategic direction, refining goals and methods, approaching collaborations (with both partners and funders),
and mapping/measuring success.
learn more about our expertise in strategic and business planning.
11.10.11: Genetic Test Offerings to the American Population
Boston, MA
Kristin Pothier, Partner, joined Louis Hochheiser, MD, VP & Chief Medical Leader of Humana Inc.; Glen Stettin, MD,
CMO of Medco; and, Matthew Zubiller, VP, Decision Management at McKesson Health Solutions on a panel titled,
"Genetic Test Offerings to the American Population" at the Personalized
Medicine Conference at Harvard Medical School in Boston.
Topics for discussion included CVS and Medco's
commitment to making personalized medicine an integral component to their business plan and reasons behind
the decision to offer genetic testing services to their customers; other large organizations that may be
contemplating incorporating genetics into their business plan, the reimbursement landscape and how payers
are thinking about molecular diagnostics. The panel was moderated by Troyen Brennan, MD, MPH,
Executive VP & CMO of CVS Caremark.
listen to a podcast related to this event.
learn more about our expertise in diagnostics.
learn more about our expertise in life sciences research.
10.26.11: Diagnostics: X Marks the Spot — Companion Dx in Oncology
Palace Hotel, San Francisco, CA
Vivek Mittal, PhD,Manager, participated in a panel at the 10th Annual Bio Investor Forum on
Wednesday, October 26th. Insights into the molecular and genetic basis of disease are driving
new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of
companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted
therapies for many cancers and other conditions among validated patient populations. Promising improved
treatment outcomes tailored to genetic etiology and disease pathology, the field of companion diagnostics
not only ignites the interest of clinicians and investors, but is also spurring potentially lucrative
industry partnerships. Focusing on these new markets, industry executives and investors discussed some of the most compelling new technologies and applications for companion diagnostics in oncology.
Moderator:
- Scott Allocco, President and a Co-founder, BioMarker Strategies
Panelists:
- Steven M. Anderson, PhD, Chief Scientific Officer of Oncology and Genetics, LabCorp and Monogram Biosciences
- Rollie Carlson, PhD, President, Asuragen, Inc.
- Alan Wahl, Senior Director Oncology, Global Pharmaceutical Research & Development, Abbott
- Vivek Mittal, PhD, Manager, Health Advances
learn more about our expertise in oncology.
learn more about our work in the diagnostics area.
09.27.11: The Business of Personalized Medicine: An Evolving Paradigm
Washington, DC
Mark Speers, Susan Posner, Tracy Walters, and Kristin Pothier attended AdvaMed 2011. The
yearly event provides medical device and diagnostics executives with an opportunity to engage in critical discussions ranging from regulatory
affairs and reimbursement, to IP and business development.
Kristin Pothier, Partner, delivered a presentation and panel discussion on Tuesday,
September 27th from 10:45am-12:00pm titled, "The Business of Personalized Medicine: An Evolving Paradigm." The presentation focused on
personalized medicine and the collaborative models in existence today, discussed the advantages and disadvantages of each option, and highlighted
the most attractive models for the future. Kristin was joined by a distinguished panel including:
- Dr. John Beeler, Director, Theranostics and Business Development, bioMérieux
- Dr. Karen Long, Divisional VP, Medical, Regulatory and Clinical Affairs, Abbott Molecular
- Dr. Elizabeth Mansfield, Director, Personalized Medicine, Office of In Vitro Diagnostics, Center for Devices and Radiological Health, FDA
learn more about our expertise in medical devices.
learn more about our expertise in diagnostics.
09.16.11: Objectively Assessing the Market Opportunity: Implications for Company Valuation and Product Strategy
Palo Alto, CA
Susan Posner, Vice President, moderated a panel at the MDMA conference for Medical Technology Executives. A medtech executive's job is to
champion the Company's product and technology, but unrealistic market expectations and imprecise descriptions of compelling value propositions
across stakeholders can lead investors to prematurely discredit a solid market opportunity and handicap the Company's ultimate commercialization
strategy.
A panel of seasoned investors and executives joined Susan to discuss accurately assessing a product's value across decision-makers and
sizing the market opportunity to both effectively position a product for market success and/or a rewarding exit.
Panel:
- Wende Hutton, General Partner, Canaan Partners
- Mike Kleine, President & CEO, EndoGastric Solutions
- David Stoffel, MD, Senior Director, New Business Development, Intuitive Surgical, Inc.
- Susan Posner, Vice President, Health Advances, LLC
learn more about our expertise in medical devices.
07.26.11: Health Advances Reception and Panel, The Evolution of Translational Tools: The Promise of Life Sciences in the Clinical World at the 2011 AACC Annual Meeting
Atlanta, GA
Kristin Pothier, Donna Hochberg, Vivek Mittal, and Brittany Carroll
attended the 2011 Annual Meeting of the American Association of Clinical Chemistry Conference (AACC). The AACC Annual Meeting
is an excellent opportunity to participate in a variety of discussions and activities surrounding the clinical in vitro diagnostics
industry. Health Advances hosted a reception, The Evolution of Translational Tools: The Promise of Life Sciences in the Clinical
World focusing on the transition of research tools into the clinical laboratory. The event included an
exciting panel with Rahul Dhanda of T2 Biosystems, Scott Garrett of Water Street Healthcare Partners, and Kevin Hrusovsky of Caliper
Life Sciences and was moderated by Kristin Pothier, Partner, Health Advances.
learn more about our expertise in diagnostics and discovery tools and read our latest publications.
07.11.11: Commercializing Companion Diagnostics: Successful Partnerships Conference
San Mateo, California
While there is much discussion and hype surrounding the value and importance of furthering the integration of personalized
medicine within healthcare systems throughout the world, in order to realize the dream and vision of personalized medicine,
much work remains to ensure that diagnostic tests are fully partnered with these new and unique therapies.
The Commercializing Companion Diagnostics Conference seeks to highlight critical success factors in making personalized
medicine a reality.
Vivek Mittal, Manager, and Gary Gustavsen, Manager, presented on two key hurdles to achieving this goal:
"Companion Diagnostics: Necessary Evolution of Medicine"
Advancement beyond the diagnosis and treatment of disease based on broad clinical symptoms to identification and treatment of discrete patient segments based on similar molecular characteristics requires increasingly complex diagnostics. These diagnostics must be seen as the enablers to providing patients with safer and more efficacious therapeutic options. Advancing patient care must align economic incentives and reward both drug & diagnostic innovators.
- Recognizing diagnostics as enablers of novel therapeutics
- Changing the economic view for paired drug-diagnostic combinations
- Overcoming competitive risks of diagnostic development
"Regulatory Perspectives on Clearance Routes for Companion Tests"
Navigating a companion test through the unclear FDA regulatory process can seem impossible without first considering the proper pathway and timeline allowing for additional information to be presented to the FDA in order to support approval. It is important to understand what is expected by the FDA on all aspects of developing a companion test and also to realize the low re-sources the FDA has to regulate appropriately which leaves much of the process misunderstood on what is expected.
- Review of recent changes in regulatory standards enforced by the FDA
- Focus on proper steps and timeline of a regulated companion test
- Discussing FDA's plans of an open guideline of what is expected
- Case study of a successful companion test approval through CDER
learn more about our work in the diagnostics area.
06.29.11: Health Advances Presentation at BIO
Washington, DC
Kristin Pothier, Partner, was part of a panel of diagnostic and drug industry experts who presented the findings
from two important reports about the reimbursement challenges facing personalized medicine diagnostics. In addition to
Kristin, the panel included Scott Allocco, President, BioMarker Strategies, LLC; David Parker, Ph.D., Vice President,
Boston Healthcare; and Steve Phillips, Director, Health Policy and Reimbursement, Johnson & Johnson. Kristin presented
the findings from the detailed report developed with BIO called The Reimbursement Landscape for Novel Diagnostics:
Current Limitations. Real-World Impact, and Proposed Solutions. Co-author Gary Gustavsen, Manager was also in attendance.
learn about our recent report on diagnostic reimbursement reform.
read the report now (PDF: 1.8MB).
learn more about our work in the diagnostics area.
06.27.11: Health Advances Workshop at Molecular Diagnostics for Cancer Drug Development Conference
Boston, MA
Kristin Pothier, Partner, and Gary Gustavsen, Manager, led the first pre-conference workshop entitled "Reimbursement for
Personalized Medicine Diagnostics: Current Limitations and Evolving Strategies"
This interactive workshop provided participants with a detailed view of the reimbursement landscape today as it pertains
to personalized medicine diagnostics. The real-world impact of current limitations were analyzed including coverage,
coding, and payment. Successful reimbursement strategies were also discussed. Then, through a series of interactive,
facilitated breakout sessions, participants were led through the most promising proposed solutions to the current
reimbursement limitations and weighed the relative benefits and disadvantages from various stakeholders' points
of view. Finally, Health Advances shared its insights for capturing the true value of personalized medicine
diagnostics today and amid potential reform environments in the future.
learn about our recent report on diagnostic reimbursement reform.
read the report now (PDF: 1.8MB).
learn more about our work in the diagnostics area.
06.14.11: Mark Speers Leads Commercialization Strategy Panel at Wilson Sonsini Goodrich & Rosati Medtech Conference
San Francisco, CA
Mark Speers, Partner and Managing Director, was joined by Michael Devine, EVP, Sales & Marketing, Access Closure, Bill Facteau,
Worldwide President, Acclarent, Inc., a division of Ethicon, Inc. and Chad Cornell, VP Corporate Development, Medtronic, Inc.
as they discussed product commercialization options and their impact on private company valuation. The panel generally agreed
that a swing in the M&A environment has occurred over the last two years and companies should think twice before scaling up
large sales and marketing infrastructures.
see a video of the panel.
learn more about our work in the medical devices area.
05.17.11: Personalized Medicine Summit Series: Reimbursement Challenges for Novel Diagnostics
Cambridge, MA
Kristin Pothier, Partner, and Gary Gustavsen, Manager, led the first workshop in the 2011 MassBio
Personalized Medicine Summit Series.
This workshop gave attendees a broad overview of the reimbursement landscape for novel
diagnostics and armed them with strategies for navigating the field in the future. Health Advances
drew on its recently published report with BIO to set the stage for an interactive discussion.
The current challenges in coverage, coding, and payment were explored. Participants shared perspectives on the real-world impact of these limitations and successful strategies
for reimbursement. Finally, the group analyzed proposed reform solutions and discussion the implications
for key stakeholders.
learn more about our work in the diagnostics area.
04.20.11: BayBio Annual Conference 2011: Powering Global Innovationg
Hyatt Regency SFO, Burlingame, CA
With Northern California regarded as a global innovation engine, the BayBio2011 Annual Conference explored themes and topics
focusing on fostering global collaborations in research, development and commercialization.
The BayBio2011 Annual Conference attracted more than 1,000 life science professionals from around the globe.
Health Advances sponsored the Regulatory and Commercialization track. Vivek Mittal, PhD, Manager moderated an exciting panel discussion,
"Integrating Product Development and Corporate Strategies" exploring how companies assess tradeoffs such as time, cost, probability of
regulatory success and commercial regulatory potential when making development decisions.
learn more about our work in the biotechnology area.
03.22.11: MassBio Annual Meeting
Royal Sonesta Hotel, Cambridge, MA
Kristin Pothier and Gary Gustavsen moderated a pair of expert panels on personalized medicine at the 2011 MassBio
Annual Meeting in Cambridge, MA. Gary moderated the panel "Applying Lessons Learned in Oncology
to Other Treatment Areas" at 8:00am and Kristin moderated the panel "Business Models in Personalized Medicine:
An Evolving Paradigm" at 11:00am.
learn more about our work in diagnostics.
02.23.11: Molecular Med Tri-Conference
San Francisco, CA
Kristin Pothier spoke at the 2011 Molecular Medicine Tri-Conference on a panel titled, "Expert Reimbursement Panel: The Changing Landscape of Valuation and Reimbursement". The conference is a premier event focused on innovations in molecular medicine, diagnostics, and life science tools.
learn about our recent report on diagnostic reimbursement reform.
learn more about our work in the diagnostics area.
02.15.11: AAOS Annual Meeting
San Diego, CA
Paula Ness Speers, Partner and Managing Director and Sheela Hegde, Vice President attended the
annual AAOS meeting in San Diego. Each year, the AAOS meeting highlights important
clinical issues and trends in the orthopedic industry that drive the future demand for medical
products and services. Senior members of the Health Advances team regularly attend the leading orthopedic
conferences, such as AAOS and NASS, as part of our ongoing commitment to stay up to date on
changes to products, policies and practices in the field.
Health Advances has considerable expertise across all segments of the orthopedics market,
including large joints, extremities, spine, trauma, sports surgery and biomaterials. As
one of our core practice specialty areas, Health Advances has developed and maintains a
deep working knowledge of the industry that can be levergaed for each new project
in the field.
Past projects have included market assessments, financial forecasts, comparative
effectiveness studies, pricing and reimbursement strategy, technology assessments, and deal due diligence,
to name a few. The analytic rigor, extensive knowledge of data resources,
understanding of the drivers of success as well as challenges facing the various
sectors within orthopedics, ensure every project we complete delivers the most
reliable and leading edge thinking to address our clients' most pressing questions.
For more information, contact us at 781-647-3435.
learn more about or expertise in orthopedics.
download our orthopedics brochure. (PDF 243KB)
register for the conference.
02.08.11: Third Annual Progress Toward Winning the War on Cancer Conference
Merck Research Labs, 33 Avenue Louis Pasteur, Boston, MA
As part of our ongoing effort to keep abreast of current issues in the healthcare industry,
Aidan Finlay, Senior Analyst, attended this symposium presented by MassBio and the American
Cancer Society. The Cancer Research Challenge presents an opportunity to create visible connections
between science, medicine and patient health and to accelerate the pace of progress against
cancer. Speakers include Joan Brugge, PhD (Louise Foote Pfeiffer Professor and Chair of
Cell Biology at Harvard Medical School) and Ed Harlow, PhD (CSO, Constellation Pharmaceuticals) and
Ulrik Nielsen, PhD (SVP and CSO, Merrimack Pharmaceuticals).
learn more about our expertise in the area of oncology.
01.29.11: Skip Irving Moderates Entrepreneurship Panel at the
Harvard Business School Healthcare Conference
Harvard Business School, Cambridge, MA
Skip Irving, Partner and Managing Director at Health Advances, moderated a panel at the Harvard
Business School's 8th Annual Healthcare Conference. The focus was on launching a biotech/pharma/device
company in the current regulatory environment. Skip was joined by an impressive group of panelists which should
lead to an interesting discussion.
Entrepreneurship Panelists:
David Berry, Partner at Flagship Ventures
Amar Sawhney , CEO and President at Ocular Therapeutix
Robert Kamen, Entrepreneur-in-Residence at Third Rock Ventures
Terry McGuire, Co-Founder and General Partner at Polaris Ventures
Micah Rosenbloom, Co-Founder at Brontes Medical
01.25.11: Personalized Medicine: State of the Industry
MassBio, One Cambridge Center, 9th Floor, Cambridge
Kristin Pothier, Partner, and Gary Gustavsen, Associate, presented their State of the
Industry perspective on personalized medicine. Following up from MassBio's Personalized Medicine Summit last September,
MassBio continues to promote the education, awareness, and business challenges surrounding
personalized medicine, kicking off the 2011 season with this State of the Industry Event.
This event was designed to familiarize MassBio's membership with the issues facing our
industry regarding PM. Health Advances walked through the complexities facing
personalized medicine especially as it impacts commercialization strategies within
biomarker research, drug discovery and development, clinical diagnostics, and companion approaches.
Health Advances recently released a report with BIO on diagnostics reimbursement
reform, a necessary step in the successful realization of personalized medicine.
learn more about our expertise in personalized medicine.
read our latest report on the Dx reimbursement landscape (PDF: 1.8MB).
request a paper copy of the report.
1.12.11: Health Care Private Equity Association (HCPEA)
San Francisco, CA
HCPEA represents 48 private equity firms focused on health care industry investments. The industry
association held its annual awards dinner during the JP Morgan conference in January. Over 80 executives
attended and recognized Russ Carson for his lifetime contributions to the industry and society.
Mark Speers, Managing Director and Partner, provided the key note address which summarized 2010 investment
activities and compared them to the previous decade. 2010 saw investment activity, in volume if not in deal size,
return to historic highs and also witnessed 4 of the largest exits in the history of healthcare private equity:
Talecris, Parkway Holdings, Multiplan, and US Oncology. Healthcare services have grown over time as a percentage
of deal flow while medical equipment and supplies have fallen in their representation.
Health Advances often performs commercial diligence for private equity firms and has now worked with over 42
different private equity firms on dozens of deals.
learn more about our experience in the area of private equity.
learn more about HCPEA.
10.08.10: MassMEDIC Medtech Investors Conference
Campus Center, UMass Boston, Boston, MA
MassMEDIC's MedTech Investors Conference has become a seminal event for the industry; drawing more
than 400 attendees from the sector's financing, consulting and manufacturing sectors.
Despite the regulatory, financing and health reform changes confronting our industry, aggressive executives
are pursuing new opportunities presented by these changes. In his speech, "The Device and
Diagnostics Industry: Where We Stand Today", Mark Speers, Partner and Managing Director, discussed five reasons to be bullish
about our critical industry's future.
view the presentation (PDF 1,554KB).
learn more about our expertise in medical devices.
09.22.10: Health Advances Presents Putting Your Best Foot Forward for Launch
Waltham, MA
Vice President Susan Posner will lead a session
on preparing a medical device product for launch.
Effectively positioning your product with the right decision makers in the optimal market segments can
catalyze adoption and set the foundation for broader use. Who are all the potential decision-makers and
influencers? Is convenience a greater value driver than clinical effectiveness? How important is the
safety aspect? How does the hierarchy of attributes vary by decision-maker? When will comparative
effectiveness data impact adoption?
Susan shared examples of how successful products have developed new markets by engaging
new decision makers and highlighting less obvious value propositions. Susan described the mapping
of value propositions to decision makers and developing a road map for targeting sequential decision
makers and market segments over time. The session also discussed when comparative effectiveness data
will be most valuable in the future.
- Positioning for success: Understanding a product's value proposition and how it may
differ depending on the decision-maker and market segment
- Comparative effectiveness and systems economic data: What is it and do we need it?
- Product launch lessons learned: A survey of the industry
view the presentation (PDF 3,172KB).
learn more about our expertise in medical devices.
07.25.10: Health Advances at 2010 AACC Annual Meeting
Anaheim, CA
Kristin Pothier, Donna Hochberg,
Kimberly Howland, Mark Speers,
Gary Gustavsen, and Marcus Moreno represented Health Advances
at the 2010 Annual Meeting of the American Association of Clinical Chemistry
Conference (AACC) July 25-29, 2010. The AACC Annual Meeting is an excellent opportunity to
participate in a variety of discussions and activities surrounding the clinical in vitro
diagnostics industry including exploring novel biomarker development and innovative diagnostic
technologies, networking with business executives, clinicians, laboratorians, and scientists,
and attending the largest clinical expo in the world.
learn more about our expertise in diagnostics and discovery tools and read our latest publications.
06.21.10: Health Advances Leads Personalized Medicine Workshop
Boston
Kristin Pothier, Vice President, and Gary Gustavsen, Associate, led a dynamic workshop entitled
“Commercializing Companion Diagnostics: From Concept to Reality.” Clinical laboratory tests
account for less than 2% of Medicare spending, but influence 70% of healthcare decisions. This
statistic becomes even stronger with emerging companion diagnostics. However, most diagnostic
test reimbursement today does not reflect the value of these technologies or the evolution of
healthcare towards a more personalized system.
These and other issues are magnified for companion diagnostics, where questions on overall
commercialization strategy and the ultimate ROI for companion diagnostic developers are
paramount and differ depending on the developer’s point-of-view.
This interactive workshop allowed participants to understand the pain points of the
current system from both a diagnostics development and a therapeutics development
perspective. Participants received a detailed view of the state of companion diagnostic
development today, saw tangible examples of recent successes and failures, and discussed
the most common pain points from several perspectives. Participants were then led through the essential questions and
resulting analyses that must be developed within all personalized medicine programs for
therapeutics and diagnostics companies. Finally, Health Advances shared its insights
for capturing the true value of companion diagnostics for all stakeholders in the future.
learn more about our expertise in personalized medicine.
05.03.10 and 05.04.10: Health Advances Sponsors Partnering for Global Health Forum, Releases New Report
Chicago
Health Advances was pleased to be a Gold Sponsor of the Partnering for Global Health Forum, an important event hosted
by BIO Ventures for Global Health (BVGH) focused on market-based solutions serving the health needs of the world’s
poorest. The Forum was held on May 3, 2010 at the McCormick Place Lakeside Center in Chicago, immediately
preceding the BIO International Convention.
On Tuesday, May 4, 2010, Health Advances, in conjunction with BVGH, unveiled a new report, “Diagnostics Innovation
Map: Medical Diagnostics for the Unmet Needs of the Developing World.” Paula Ness Speers, Managing Director and
leader of Health Advances’ Global Health Practice and Kristin Pothier, Vice President and leader of the Diagnostics
and Discovery Tools Practice, participated in the presentation of summary findings.
The Diagnostics Innovation Map explores some of the most innovative current and emerging diagnostic technologies and provides insight into how these technologies might be applied to developing world settings. The report clarifies the diagnostic requirements for resource-poor settings and explores how recent and emerging technological advancements in the developed world might be used to improve patient care and save lives in the developing world.
The report provides:
- An understanding of unmet diagnostic needs for neglected diseases and the performance requirements for diagnostics
used in resource-poor settings
- An overview of the value that novel diagnostics can bring to health care in resource-poor settings
- Examples of innovative lab-based and point-of-care (POC) technologies and analysis of how these recent advances
could address unmet diagnostic needs in the developing world
- Resources to aid in forging new partnerships to accelerate the development of diagnostics for neglected diseases.
In addition to their presentation of the Diagnostics Innovation Map, Paula Ness Speers and Kristin Pothier participated
in BIO’s One-on-One Partnering meetings, part of the Business Forum at the 2010 BIO International Convention. One-on-One
Partnering is the world’s largest biotech partnering event, allowing companies to connect with investors, senior scientific
and business management professionals and create opportunities for collaboration and innovation.
learn more about Health Advances’ expertise in the area of global health.
05.04.10: Biotechnology Industry Organization — Think and Drink Event
Chicago
Health Advances hosted its highly popular “Think & Drink” event at the BIO International Convention. This year’s event, a dynamic,
interactive forum guided by industry leaders, was entitled “Follow-on Biologics – Strategy Ends
that Justify the Means.”
Skip Irving, Partner
at Health Advances moderated the discussion. Federico Pollano, CEO of Richter-Helm BioTec, Dr. Mark McCamish, Head Global Biopharmaceutical Development
of Sandoz International, and Dr. Shyam Bishen, VP, Corporate Development at Ranbaxy Pharmaceuticals joined Kimberly Howland, PhD, Vice President at Health Advances to offer their take on
opportunities in the market and which companies have the best chance of success in this complex and expensive arena.
During this highly interactive event, the audience had the opportunity to weigh in on whether biologics can generate a positive return, what the model for
success looks like, which products offer the greatest potential for follow-on biologic penetration, where and how branded
biologic companies will defend their position, and many more key issues surrounding follow-on biologics.
04.22.10: Keynote at BIOMEDevice Forum
Boston Convention & Exhibition Center
9:15am: Keynote Presentation: Integration of Therapeutics and Diagnostics: Lessons Learned from the Front Line
Kristin Pothier, Vice President
Developing, commercializing, and generating return on personalized medicine has been a dilemma for many stakeholders to date,
as the success of each program is highly dependent on a number of factors that are not always aligned among different
stakeholders. Therapeutics companies, diagnostics companies, and service providers each have different approaches and goals
in helping bring personalized medicine to market. Now, more than ever, they are realizing the need for and positive impact of
carefully crafting an internal personalized medicine strategy and working together in successful, mutually beneficial partnerships.
9:45am: Keynote Panel
A lively discussion with executives from leading therapeutics, diagnostics, and life sciences companies who have spearheaded personalized medicine initiatives and have found ways to collaborate effectively for maximum return.
Panelists:
Iain Miller, Ph.D., Executive Director, Theranostics Strategy and Business Development, bioMérieux
Steve Bushnell, Ph.D., Sr. Director, Discovery Translational Medicine, Biogen Idec
Lee Babiss, Ph.D., Executive Vice President of Global Laboratory Services, PPD (formerly of GSK and Roche)
Gary Gustavsen, Associate, Health Advances (moderator)
learn more about Health Advances’ expertise in diagnostics.
02.05.10: Daniel Selvig Attends 2010 Highlights of ASH Meeting in San Francisco
Daniel Selvig, Consultant at Health Advances, represented Health Advances at the 2010 Highlights of ASH Meeting February 5-6, 2010. The meeting will feature leading hematology experts who will present analysis of the ASH annual meeting abstracts, evolving therapies, and the latest treatment options. In addition, daily panel discussions and programs such as “Breakfast with the Experts” will provide the opportunity to discuss real patient cases with leaders in the field, gain knowledge that can impact patient care strategies, and network with colleagues.
learn more about our expertise in Oncology and Hematology.
01.30.10: Skip Irving Moderates Panel at HBS
Skip Irving, Partner and Managing Director at Health Advances, moderated a panel at Harvard Business School’s 2010 Healthcare
Conference. The panel, presented by the Healthcare Club at HBS, was entitled “Venture Capital & Entrepreneurship — Will Policy
Changes Kill Innovation in Healthcare?” Joining Skip on the panel were:
Bonnie Fendrock, President and CEO, Hepregen Corporation
Jeffrey Levin-Scherz, Principal, Towers Perrin
Tom McKinley, General Partner, Cardinal Partners
12.10.09: Kristin Pothier Participates in BIOMEDevice Forum in San Jose
In recent months, DTC genomics has been under intense scrutiny. Kristin Pothier, Vice President, Health Advances,
addressed this topic on December 10th at the 2009 BIOMEDevice Forum in San Jose, CA. She was joined
by Amy DuRoss, Vice President of Policy and Business Affairs, Navigenics; Leah Sparks, Sr. Director, Business
Development, DNA Direct; and Sandra Lee, Ph.D. Senior Research Scholar, Stanford University. The panelists
discussed how each has navigated through the regulatory, ethical, and business issues surrounding direct-to-consumer
diagnostics, what their greatest drivers and barriers are today, and how these controversial offerings may change
in the future.
learn about Health Advances’ expertise in diagnostics and discovery tools and read our latest publications.
12.03.09: Marie Schiller and Skip Irving Participate in Faster Cures Conference
Marie Schiller, Partner, and Skip Irving, Partner and
Managing Director, represented Health Advances at the FasterCures conference in New York
City. “Partnering for Cures” was a first-of-its-kind meeting that brought together philanthropy,
medical research foundations, and the biopharmaceutical industry in an effort to forge strategic
collaborations key to the timely development of new medical solutions. In addition to attending the conference,
Marie Schiller participated in a panel discussion entitled “Stories from the Front Lines of Philanthropy.”
Panel members shared their thoughts on philanthropic investment and collaboration in the battle to conquer
deadly diseases.
Speakers
Dana Ball, Program Director
David Panzirer - Trustee
Melissa Berman, CEO & President for Rockefeller Philanthropy Advisors
Marie Schiller, Partner – Health Advances
Doug Melton, Harvard Stem Cell Institute
Alan Lewis, CEO - JDRF
11.10.09: Paula Ness Speers attends Major Orthopedics Meeting in San Francisco (NASS)
Paula Ness Speers, Partner and Managing Director at Health Advances, participated in the annual meeting of the North American Spine Society in San Francisco during the week of November
10th. Health Advances has extensive experience in orthopedics. We have worked with clients on a variety of projects such as new
product design assessments, market sizing for new orthopedic products, and pricing and reimbursement strategies prior to market
launch. The firm also supports major transactions for strategic and financial clients interested in orthopedics products or
companies by conducting due diligence for licensing or acquisition activities.
Paula oversees the majority of our work in the orthopedic sector and can be reached by calling the firm’s Boston area office at 781-647-3435.
11.09.09: Health Advances Hosts VIP Reception for Executives interested in Vaccines and Global Health at the Broad Institute, Cambridge, MA
Health Advances hosted a VIP reception for approximately 80 executives interested in better understanding opportunities for vaccines in the global
health arena on November 9th at the Broad Institute in Cambridge. The reception preceded the MIT Enterprise Forum’s program titled: Vaccines & Global
Health: New Technologies Create Global Opportunities.
Paula Ness Speers, Partner and Managing Director at Health Advances, leads the firm’s Global Health practice area, which works with a range of
clients, including non-profit global health organizations and for-profit companies developing products with potential applications in the developing world.
To learn more about our experience in the areas of vaccines and global health, please call Paula Ness Speers at Health
Advances’ Boston area office: 781-647-3435.
07.21.09: Has Point of Care Come of Age?
The logic of POC testing, enabling rapid diagnosis and treatment, has been impeccable for decades.
Nevertheless, relatively few POC tests have become commercial successes. Will a more cost-conscious
healthcare system catalyze or impede the adoption of more POC testing? Which POC innovations will
move the needle? What is the future of POC testing in the US and ROW? Some of the industry's pioneers
joined us for a lively debate on this topic during the year’s AACC in Chicago, IL.
Panelists:
Kristin Pothier, Vice President, Health Advances (Moderator and Presenter)
Kent Lewandrowski, Editor-in-Chief, Point of Care Journal
David Lewis, Executive Director, Morgan Stanley-Research
Robert Kunkler, Divisional Vice President, Business Development, Abbott POC
John McDonough, CEO, T2 Biosystems
Douglas Michels, President and CEO, OraSure Technologies
Clinton Severson, Chairman, President and CEO, Abaxis
learn about Health Advances’ expertise in diagnostics and discovery tools and read our latest publications.
06.09.09: Consumer Genetics Show
Philina Lee, PhD, Associate at Health Advances, will address the challenges of biomarker
commercialization at the First Annual Consumer Genetics Show at the Hynes Convention Center
in Boston, June 9-11, 2009. This premier genetics show will gather companies and
organizations involved in DTC genetic testing, genetic research, healthcare, and
law to discuss issues facing the field: best practices, how to navigate the healthcare
system, scientific and technological advances, legal and regulatory challenges, and more.
learn more about Health Advances’ expertise in complex diagnostics and read about our latest publications.
04.22.09: BIOMEDevice Forum
Kristin Pothier, Vice President and Susan Posner, Vice President participated in the
BIOMEDevice Forum, New England's premier executive-level conference focusing on convergence
and cross-sector collaborations among companies in the biotechnology, medical device, IVD,
and pharmaceutical industries. This two-day event brought together key players involved in
investing, partnering, licensing, and developing business opportunities in the rapidly growing
market for innovative healthcare products.
Drug Delivery and Diagnostics
Kristin Pothier, Vice President, Health Advances (Moderator)
Kristin assembled and led senior executives from Allegro Diagnostics, Genzyme Corporation,
Infinity Pharmaceuticals, SeraCare Life Sciences, and BG Medicine on a panel discussion of “Drug
Delivery and Diagnostics,” exploring how different companies are harnessing the power of
drug/diagnostic convergence to push both innovation in the space and corporate objectives forward.
Joining Kristin on the panel were:
Dan Rippy, President & CEO of Allegro Diagnostics
Joan Keutzer, Vice President, Scientific Affairs, Genzyme Corporation
John Evans, Director of Product Development, Infinity Pharmaceuticals
Michael Steele, Vice President- Business Development, SeraCare Life Sciences
Gregg Mayer, Vice President, Diagnostic Strategy, BG Medicine
Convergent Technologies Present Unique Regulatory and Clinical Challenges
Susan, along with David Fox of Hogan & Hartson LLP and Tom Hutchinson of Davol (CR Bard),
led a discussion on the unique challenges posed by combination products and convergent
technologies in the clinical pathway and regulatory processes. Susan offered her
wide-ranging expertise in the device sector and discussed specific strategies that can be
used along the regulatory and clinical paths to avoid pitfalls and maximize revenues.
03.26.09: Is There a Business Model for Companion Diagnostics?
Kristin Pothier, Vice President, Health Advances, moderated “Is There a Business
Model for Companion Diagnostics?” as part of Windhover’s groundbreaking webinar series, Pharma Business Strategies for Biomarkers. The
webinar provided thought-provoking analysis of the evolving concept of how a biomarker may ultimately become linked to a diagnostic
product opportunity — as a predictive test to select patients more likely to respond to a drug or class of drugs, or as a way to monitor
a response to one. But diagnostics development costs are soaring with greater demands for validation from prospective clinical trials,
and pharma companies have been reluctant to support these efforts. Where are diagnostics companies turning for support and funding? Which
high-value opportunities can sustain a business? Is collaboration the answer, and if so, in what form?
Joining Kristin were Mickey Urdea, CEO of Tethys Bioscience; Rosanne Welcher, PhD, MBA General Manager & VP, R&D of The Dako Group;
Iain Miller, Senior Director, Oncology Strategy and Theranostics, BioMérieux; and Peter
Collins, Senior Vice President of Business Development, DxS
see webinar presentation (PDF: 318KB)
02.26.09: Due Diligence – The Un-sung Hero in the Deal Process
Marie Schiller, Partner at Health
Advances, shared her views on the deal process at a meeting of the Massachusetts
Biotech Council (MBC) in Cambridge, MA. Marie was joined by panelists from the pharmaceutical
industry to discuss due diligence in the transaction process, including buyer and seller
perspectives and best practices. Marie’s expertise in guiding corporations through
business and scientific analyses on product development, market positioning, and corporate
strategy as well as her M&A experience complemented insights from these industry panelists:
Janice Olson, VP of Program Management, Genzyme; Young T. Kwon, Director, New Ventures and
Business Development, Biogen Idec; Philip T. Chase, VP of Legal, Alnylam Pharmaceuticals, Inc.;
and Clare Fisher, Senior Director, Oncology Business Development, Genzyme Corporation.
|
|
 |
|
|
|
|
